Qilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2022 Jiuquan, China

Qilian International Holding Group Limited Reports

Financial Results for the First Six Months of Fiscal Year 2022

Jiuquan, China, September 30, 2022 (GLOBE

NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical

products manufacturer, today announced its unaudited financial results for the first six months of fiscal year 2022 ended March 31, 2022.

Xin, Chairman and CEO of the Company, commented, "Under the impact of uncertain political climate and COVID-19 variants,

the prices of agricultural and energy products have been increasing globally in 2022, which also led to reduced profitability of the manufacturing

industry in general. Our half-year report in 2022 presents a revenue of approximately US$32.1 million, an increase of 7% over our revenue

during the same period of time in previous year. Our profit fell by 89% to US$249,681 due to increasing raw material prices, as compared

to our profit during the same period of time in previous year. "

"We expect to complete certain construction

projects in 2023. Along with expected control of COVID-19 pandemic in China, we expect the company's new growth in 2023."

Financial Highlights for the Six Months Ended

increased by 7% year-over-year to $32.1 million for the six months ended March 31, 2022 from $29.9 million for the same period of the

prior fiscal year. The increase in revenue is primarily attributable to the increased sales from heparin products and Sausage casing,

and natural fertilizer and the appreciation Renminbi ("RMB") against U.S. dollars ("USD"), from an average exchange

rate of 1 USD = 6.5541 RMB for the six months ended March 31, 2021 to an average exchange rate of 1 USD = 6.3712 for the six months ended

Gross profit decreased by 31% to $2.8 million for the six months ended March 31, 2022 from $4.1 million for the same period of the prior fiscal year. Gross margins were 8.8% and 13.7% for the six months ended March 31, 2022 and 2021, respectively. The decreased gross profit was mainly due to decreased gross margin from licorice products, the cost per unit of which has increased significantly compared to the six months ended March 31, 2021.

Income from operations was $1.2 million for the six months ended March 31, 2022, compared to income from operations of $2.3 million for the same period of the prior fiscal year, due to the decrease of gross profit.

Net income was $0.2 million for the six months ended March 31, 2022, compared to net income of $2.2 million for the same period of the prior fiscal year mainly due to the decreased gross margin described above and increased investment loss from marketable securities.

Net income attributable to Qilian International was less than $0.1 million or earnings per share of $0.00 for the six months ended March 31, 2022, compared to net income attributable to Qilian International of $2.4 million, or earnings per share of $0.07, for the same period of the prior fiscal year.

Unaudited Financial Results for the Six months

ended March 31, 2022

For the six months ended March 31, 2022, revenue

increased by $2.1 million, or 7%, to $32.1 million from $29.9 million for the same period of the prior fiscal year. The increase was mainly

due to the sales increase from heparin products and Sausage casing, and natural fertilizer, as well as the appreciation of RMB to USD

for the six months ended March 31, 2022.

For the six months ended March 31, 2022, revenue

from heparin products increased by $0.8 million or 9.9%. The increase was due to increase quantity of heparin products sold. The quantity

of heparin products sold increased by 31% from 1.0 million grams for the six months ended March 31, 2021 to 1.3 million grams for the

six months ended March 31, 2022 , which contributed $2.4 million of increased sales and was mainly driven by increased demand from pharmaceutical

customers. Due to the COVID-19 Omicron variant continued to develop globally, global demand for prescription medicines, vaccines and medical

devices increased. This increase was partially offset by the decrease of average selling price by 16% from RMB 51 per gram for the

six months ended March 31, 2021 to RMB 43 per gram for the six months ended March 31, 2022 , which contributed to a $1.6 million decrease..

For the six months ended March 31, 2022, revenue

from oxytetracycline products, licorice products and TCMD increased by approximately $0.4 million, or 2%. The increase was due to the

appreciation of RMB to USD for the six months ended March 31, 2022. Renminbi ("RMB") against U.S. dollars ("USD")

exchange rate changed from an average exchange rate of 1 USD = 6.5541 RMB for the six months ended March 31, 2021 to an average exchange

rate of 1 USD = 6.3712 for the six months ended March 31, 2022. For the six months ended March 31, 2022, the sales denominated in RMB

for oxytetracycline products, licorice products and TCMD decreased by approximately RMB 1.3 million, or 1%, from approximately RMB 127.7

million for the six months ended March 31, 2021 to approximately RMB 126.5 million for the six months ended March 31, 2022. The average

selling price of oxytetracycline products decreased by 5% from RMB77 per unit for the six months ended March 31, 2021 to RMB 73 per unit

for the six months ended March 31, 2022 in order to stimulate sales of the products. These decreases were partially offset by an increase

in quantity of oxytetracycline products, licorice products and TCMD sold by 3%, due to the lower selling price.

For the six months ended March 31, 2022, revenue from fertilizer increased

by $0.5 million or 254.8%. In the fiscal year ended September 30, 2021, we expanded our manufacturing capacity and the production of fertilizer

was interrupted for almost ten months. Limited products were manufactured for the six months ended March 31, 2021. We resumed normal production

of fertilizer in October 2021.

The appreciation of RMB against USD contributed

$0.9 million increase of revenue for the six months ended March 31, 2022.

Cost of revenue increased by $3.4 million, or

13%, to $29.3 million for the six months ended March 31, 2022 from $25.8 million for the same period of the prior fiscal year. The increase

in overall cost of revenue was mainly due to the following reasons: (1) increase of sales from heparin products and Sausage casing, and

natural fertilizer, which increased cost of revenue by $0.7 million and $0.4 million respectively; (2) increase of cost from oxytetracycline

products, licorice products and traditional Chinese medicine derivatives ("TCMD") of $2.3 million and (3) appreciation of

RMB against USD, which contributed $0.8 million increase of cost of sales.

Gross profit decreased by $1.3 million, or 31%,

to $2.8 million for the six months ended March 31, 2022 from $4.1 million for the same period of the prior fiscal year, mainly due to

the decrease of gross margin of $2 million from oxytetracycline products, licorice products and TCMD, partially offset by the increased

gross margin from heparin product and natural fertilizer. As a result, gross margin percentage decreased to 8.8% for the six months ended

March 31, 2022 from 13.7% for the same period of the prior fiscal year.

Gross profit margin for oxytetracycline products,

licorice products and TCMD decreased by 10.3% for the six months ended March 31, 2022 as a result of the decreased selling price for licorice

products in the current year, compared to the same period of prior year, as the price went down as demand decreased as the international

trading was affected by the war between Ukraine and Russia. On the other hand, cost per unit increased by more than 10% due to supply

chain interruption as well as the inflation in the global market, and restraint from logistics as affected by the COVID-19 pandemic. Gross

margin percentage for heparin and sausage casing products and natural fertilizer increased by 4.7% and 3.6%, respectively, for the six

months ended March 31, 2022 compared to the same period of prior year due to lower unit cost with a flat sales price per unit. The price

of raw material used for these products were less volatile as the raw materials are mainly domestically in China.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were

$1.6 million for the six months ended March 31, 2022, representing a decrease of approximately $0.2 million, or 12.4%, from $1.8 million

for six months ended March 31, 2021. The decrease was mainly attributable to decreased marketing and advertising expense of approximately

$0.2 million as we had significant IPO related marketing expense for the six months ended March 31, 2021.

Income before income taxes

Income before income taxes was $0.4 million for

the six months ended March 31, 2022, compared to income before income taxes of $2.5 million for the same period of the prior fiscal year.

Net income and net income attributable to Qilian

Net income was approximately $0.2 million for

the six months ended March 31, 2022, compared to net income of $2.2 million for the same period of the prior fiscal year. After deducting

non-controlling interests, net income attributable to Qilian International was approximately $87,862 for the six months ended March 31,

2022, compared to net income attributable to Qilian International of $2.4 million for the same period of the prior fiscal year.

Earnings per share-basic and diluted

After deducting non-controlling interests, earnings

per share attributable to the Company was less than 0.01 per basic and diluted share, for the six months ended March 31, 2022, compared

to earnings per share of $0.07 per basic and diluted share, for the same period of the prior fiscal year.

Weighted average number of shares outstanding

was 35,750,000 for the six months ended March 31, 2022, compared to 32,428,571 for the same period of last fiscal year.

As of March 31, 2022, the Company had cash of

$11.7 million, compared to $10.5 million as of September 30, 2021. Total working capital was $20.8 million as of March 31, 2022, compared

to $22.2 million as of September 30, 2021. As of March 31, 2022, the Company had bank acceptance notes payable of $9,674,845. The bank

acceptance notes payable are lines of credit extended by China Zheshang Bank that can be endorsed and assigned to vendors as payments

for purchases. As of March 31, 2022, the Company pledged $5,149,898 of the bank acceptance notes receivable to secure the bank acceptance

Net cash provided by operating activities was

$4.2 million for the six months ended March 31, 2022, compared to net cash provided by operating activities of $9.7 million for the same

period last year. The decrease of cash provided by operating activities was due to the $2.0 million decrease of net income, and decrease

of $4.0 million from change of operating assets and liability, primarily driven by the change of bank acceptance note receivable.

Net cash used in investing activities was $3.4

million for the six months ended March 31, 2022, compared to net cash used in investing activities $21.1 million for the same period last